BIOCRYST PHARMACEUTICALS

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States for the prevention of HAE attacks in adult and pediatric patients 12 years and older, and under regulatory review for approval in Japan and the European Union. BioCryst has several ongoing development prog... rams including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing.
BIOCRYST PHARMACEUTICALS
Industry:
Biotechnology Clinical Trials Therapeutics
Founded:
1986-01-01
Address:
Birmingham, Alabama, United States
Country:
United States
Website Url:
http://www.biocryst.com
Total Employee:
101+
Status:
Active
Contact:
9198591314
Total Funding:
1.31 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Google Tag Manager WordPress Content Delivery Network Font Awesome Global Site Tag Sitelinks Search Box IPv6
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Current Advisors List
Board_member
Board_member
Board_member
2008-01-01
Current Employees Featured
Charles Gayer Chief Commercial Officer @ BioCryst Pharmaceuticals
Chief Commercial Officer
2020-01-01
William P. Sheridan SVP & CMO @ BioCryst Pharmaceuticals
SVP & CMO
2014-01-01
Jinky Ang Rosselli Chief Data & Insights Officer @ BioCryst Pharmaceuticals
Chief Data & Insights Officer
2021-11-01
Nancy Hutson Director @ BioCryst Pharmaceuticals
Director
2011-06-01
Jon P. Stonehouse President & CEO @ BioCryst Pharmaceuticals
President & CEO
2014-01-01
Matthew Toczko Sr. Manager, Chemical Development @ BioCryst Pharmaceuticals
Sr. Manager, Chemical Development
2022-02-01
Anthony Doyle SVP & Chief Financial Officer (CFO) @ BioCryst Pharmaceuticals
SVP & Chief Financial Officer (CFO)
2020-04-01
Thomas R. Staab SVP & CFO @ BioCryst Pharmaceuticals
SVP & CFO
2014-01-01
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2012-10-18 | Presidio Pharmaceuticals | Presidio Pharmaceuticals acquired by BioCryst Pharmaceuticals | 101 M USD |
2010-10-14 | Bioanalytical Laboratory Services | Bioanalytical Laboratory Services acquired by BioCryst Pharmaceuticals | N/A |
Investors List
Royalty Pharma
Royalty Pharma investment in Post-IPO Equity - BioCryst Pharmaceuticals
Ontario Municipal Employees Retirement System
Ontario Municipal Employees Retirement System investment in Post-IPO Equity - BioCryst Pharmaceuticals
Royalty Pharma
Royalty Pharma investment in Post-IPO Debt - BioCryst Pharmaceuticals
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Debt - BioCryst Pharmaceuticals
MidCap Financial
MidCap Financial investment in Post-IPO Debt - BioCryst Pharmaceuticals
Centers for Disease Control and Prevention
Centers for Disease Control and Prevention investment in Grant - BioCryst Pharmaceuticals
MidCap Financial
MidCap Financial investment in Post-IPO Debt - BioCryst Pharmaceuticals
National Institutes of Health
National Institutes of Health investment in Post-IPO Equity - BioCryst Pharmaceuticals
National Institute of Allergy and Infectious Diseases
National Institute of Allergy and Infectious Diseases investment in Grant - BioCryst Pharmaceuticals
Key Employee Changes
Official Site Inspections
http://www.biocryst.com Semrush global rank: 2.09 M Semrush visits lastest month: 9.96 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago

More informations about "BioCryst Pharmaceuticals"
Home | Biocryst®
Welcome! Bienvenue! We are honoured that you are visiting BioCryst Canada. Headquartered in Toronto, we are a focused, dedicated, and passionate team of biopharma professionals with decades of collective experience serving …See details»
BioCryst Pharmaceuticals - Wikipedia
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in …See details»
BioCryst Pharmaceuticals, Inc. Management Team | Org Chart
BioCryst Pharmaceuticals, Inc. employs 634 employees. The BioCryst Pharmaceuticals, Inc. …See details»
BioCryst Pharmaceuticals - Crunchbase Company …
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an …See details»
BioCryst - Our Medicines, Clinical Trials, Congress …
BioCryst Medical AFFAIRS Navigate the Biocryst Medical Affairs Hub with ease Throughout this resource hub you will find up-to-date information on developing and approved BioCryst medicines, including clinical trials, congress …See details»
BioCryst Pharmaceuticals' Leadership Team - The Org
The leadership team at BioCryst Pharmaceuticals has a history of experience in the …See details»
BioCryst | Denmark | Home
BioCryst is a commercial-stage biotech committed to rare diseases. At BioCryst, our structure-guided drug design propels forward the discovery and development of novel, small-molecule, oral drugs for people living with rare diseases. With …See details»
About Us | BioCryst®
Learn about our mission, explore our company history, and meet our leadership team and board of directors.See details»
BioCryst Strengthens Commercial Rare Disease Leadership
Mr. Hodge joins BioCryst from Array Biopharma, where he helped to build the commercial …See details»
What are Mission Vision & Core Values of BioCryst …
4 days ago BioCryst Pharmaceuticals effectively communicates its mission, vision, and core …See details»
Contact Us in Canada | Biocryst®
Grants BioCryst offers funding to support medical grants or external research grants. Please …See details»
Careers - BioCryst®
Interested in joining BioCryst? Discover the values that drive us, meet members of our team, …See details»
Helen Thackray - Chief Research and Development Officer at …
Helen Thackray, MD, serves as the Chief Research and Development Officer at BioCryst …See details»
BioCryst | Canada | Pipeline
BioCryst are passionate about advancing novel therapeutics for patients with rare and serious …See details»
Patient Advocacy | BioCryst®
I’m passionate about patient advocacy and the vital role it plays in our mission at BioCryst.” My …See details»
BioCryst Announces Sale of European ORLADEYO® (berotralstat) …
5 days ago —Neopharmed Gentili will pay BioCryst $250 million upfront for the European …See details»
BioCryst Pharma Sells European Business for Rare Disease Drug in …
4 days ago BioCryst Pharmaceuticals is selling the European rights and assets for its top …See details»
Product Pipeline | BioCryst®
Explore our pipeline of complement-mediated and rare disease therapeutics, and learn about …See details»
BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for …
Jun 25, 2025 BioCryst (BCRX) might move higher on growing optimism about its earnings …See details»
Medicines in Canada | Biocryst®
Immediately report any adverse reaction suspected of being due to a BioCryst medication at …See details»